Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple Myeloma

Name: Adriana Rossi, MD and Luciano J. Costa, MD, PhD on Earlier CAR T in Multiple Myeloma
Uploaded: 2022-06-20T11:00:00.000Z
Description: Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.

June 20, 2022

Adriana Rossi, MD
Luciano J. Costa, MD, PhD

Video

Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.

This content originally appeared on our sister site, OncLive.

Related Content

Around the Helix: Cell and Gene Therapy Company Updates – November 29, 2023

November 29th 2023

Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Autolus Submits Obe-Cel BLA for Adult B-ALL

Autolus Submits Obe-Cel BLA for Adult R/R B-ALL

November 29th 2023

Article

The company also plans to submit an MAA to the EMA in the first half of 2024.

FDA to Investigate Risk of T-Cell Malignancy After CAR T-Cell Therapy

November 28th 2023

Article

The FDA has received reports of multiple T-cell malignancies in patients after approved CAR-T treatment.

Nexcella’s Light Chain Amyloidosis CAR-T NXC-201 Expands Clinical Trial Activities Into the US

November 28th 2023

Article

The CAR-T was already being assessed in the ongoing phase 1a/1b NEXICART-1 clinical trial in Israel ahead of this IND clearance by the FDA.

Enabling Wider Antigen Selection With Logic-Gated CAR T-Cell Therapy for Solid Tumors

November 25th 2023

Article

Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.